Smith+Nephew Backs Wimbledon Stars, Showcasing Advanced Joint Repair Solutions

Smith+Nephew (LSE:SN, NYSE:SNN), a global leader in medical technology, is once again set to provide support to select athletes at the prestigious annual Championships, Wimbledon in 2025. This iconic tournament, revered as the world’s oldest and most esteemed tennis event, offers Smith+Nephew an ideal platform to underscore its commitment to ‘Life Unlimited’—a purpose centered on enhancing patient lives through exceptional sports medicine products and cutting-edge technological advancements.

Tennis, a sport demanding peak physical performance, places immense stress on the body, particularly the joints, frequently leading to injuries. Smith+Nephew’s innovative solutions for joint repair are designed to address these challenges, featuring:

• REGENETEN^◊ Bioinductive Implant: Since its 2014 introduction, this implant has been utilized in over 150,000 procedures globally, revolutionizing the treatment of rotator cuff tears. Clinical studies demonstrate lower re-tear rates compared to traditional methods. Supported by Level I clinical evidence, this collagen-based implant aids the body’s natural healing process, fostering new tendon-like tissue formation to biologically reinforce existing tendons and potentially alter the progression of rotator cuff tears.

• CARTIHEAL^◊ AGILI-C^◊ Cartilage Repair Implant: Crafted from aragonite, a naturally occurring calcium carbonate, the CARTIHEAL Implant is a unique biphasic scaffold designed for cartilage repair and subchondral bone restoration. It has shown clinically significant improvements in post-operative pain, function, and quality of life. The CARTIHEAL Implant is the only device approved for treating cartilage and osteochondral defects in the knee, applicable to patients with or without mild to moderate osteoarthritis.

• Q-FIX^◊ KNOTLESS All-Suture Anchor: Building on the established performance and superior fixation strength of the Q-FIX Family, the new Q-FIX KNOTLESS All-Suture Anchor represents a significant advancement in all-suture anchor technology. With proprietary features and capabilities, this anchor is engineered to provide enhanced soft tissue security and offer surgeons a novel option for soft tissue-to-bone fixation across various joint applications.

“Our inaugural sponsorship of select players during The Championships, Wimbledon in 2024 was met with remarkable success, supporting athletes on their journey, including Jasmine Paolini’s impressive reach into the Ladies’ Final,” stated Christie van Geffen, SVP Global Sports Medicine Marketing for Smith+Nephew. “This partnership provided a unique opportunity to showcase the Smith+Nephew brand and our leading Sports Medicine technology portfolio, all geared towards helping both amateur and elite athletes return to competition and pursue their passions.”

For those interested in learning more about Smith+Nephew’s advanced Sports Medicine technology, including the CARTIHEAL AGILI-C Cartilage Repair Implant, the REGENETEN Bioinductive Implant, and the Q-FIX KNOTLESS All-Suture Anchor, further details are available here.

– ends –

About Smith+Nephew

Smith+Nephew is a global medical technology company dedicated to repairing, regenerating, and replacing soft and hard tissues. Our overarching mission is to restore physical function and enhance lives through innovative technology, encapsulated by our purpose: ‘Life Unlimited’. With a dedicated team of 17,000 employees, we impact patients’ lives daily through the excellence of our product offerings and the continuous development and application of new technologies across our three key global business units: Orthopaedics, Sports Medicine & ENT, and Advanced Wound Management.

Established in Hull, UK, in 1856, Smith+Nephew now operates in approximately 100 countries, achieving annual sales of $5.8 billion in 2024. Listed on both the London Stock Exchange (LSE:SN) and the New York Stock Exchange (NYSE:SNN), the ‘Group’ designation refers to Smith & Nephew plc and its consolidated subsidiaries, unless the context dictates otherwise.

For comprehensive information about Smith+Nephew, please visit www.smith-nephew.com and engage with us on X, LinkedIn, Instagram, or Facebook.

Forward-looking Statements

This document may contain forward-looking statements that are subject to change and may not prove accurate. These include statements concerning expected revenue, trading profit margins, market trends, and our product pipeline. Expressions such as “aim,” “plan,” “intend,” “anticipate,” “well-placed,” “believe,” “estimate,” “expect,” “target,” “consider,” and similar phrasing are indicative of forward-looking statements. Such statements inherently involve known and unknown risks, uncertainties, and other factors that could cause actual results to diverge materially from those expressed or implied. For Smith+Nephew, these potential factors include geopolitical events, economic and financial conditions in our operating markets, impacting healthcare providers, payers, and customers; pricing dynamics for existing and innovative medical devices; advancements in medical technology; regulatory approvals, reimbursement decisions, and other governmental actions; product defects, recalls, or issues with quality management systems; non-compliance with regulations; litigation related to patents or other claims; legal and financial compliance risks, including investigations and enforcement actions; supply chain disruptions or operational inefficiencies; competition for skilled personnel; the success of strategic actions, including acquisitions and disposals, including due diligence, valuation, and integration processes; resultant disruptions from business plan or organizational changes; relationships with healthcare professionals; reliance on information technology and cybersecurity; occurrences such as natural disasters and climate change-related events; evolving customer and stakeholder sustainability expectations; changes in taxation regulations; foreign exchange volatility; and various other political, economic, business, competitive, and reputational factors. A more detailed discussion of certain of these factors can be found in the documents filed by Smith+Nephew with the U.S. Securities and Exchange Commission, including the most recent Form 20-F annual report, accessible on the SEC’s website at www.sec.gov. All forward-looking statements are based on information available to Smith+Nephew as of the date of this statement and are subject to this cautionary notice. Smith+Nephew does not undertake any obligation to update or revise any forward-looking statement to reflect changes in circumstances or expectations.

^◊ Trademark of Smith+Nephew. Some marks are registered with the U.S. Patent and Trademark Office.